

## Anti CS[Chondroitin Sulfate] (1B5)

### BACKGROUND

Monoclonal antibody 1B5 recognises unsulfated unsaturated disaccharide neoepitopes (i.e. C-0-S "stubs") generated at the non-reducing terminal of Chondroitin Sulfate glycosaminoglycan chains that have been pre-digested with either Chondroitinase ABC or Chondroitinase ACII [see Figure 2; Caterson B (2012) Int. J. Exp. Pathol. 93: 1 - 10].

|                         |  |
|-------------------------|--|
| <b>Product type</b>     | Primary antibody   |
| <b>Immunogen</b>        | Unsulfated chondroitin sulfate disaccharide<br>Chondroitinase ABC digested Rat Chondrosarcoma Aggrecan   |
| <b>Rased in</b>         | Mouse (BALB/c)   |
| <b>Myeloma</b>          | X63-Ag8.653  |
| <b>Clone number</b>     | 1B5  |
| <b>Isotype</b>          | IgG1   |
| <b>Source</b>           | Serum containing culture supernatant   |
| <b>Purification</b>     | -  |
| <b>Buffer</b>           | 0.01M Tris-saline containing 0.02% NaN <sub>3</sub> as a preservative  |
| <b>Concentration</b>    | Not known  |
| <b>Volume</b>           | 1 mL   |
| <b>Label</b>            | Unlabeled  |
| <b>Specificity</b>      | Unsulfated unsaturated disaccharide neoepitopes (i.e. C-0-S "stubs") generated at the non-reducing terminal of Chondroitin Sulfate glycosaminoglycan chains that have been pre-digested with either Chondroitinase ABC or Chondroitinase ACII [see Figure 2; Caterson (2012) Int. J. Exp. Pathol. 93: 1 - 10]. |
| <b>Cross reactivity</b> | All animal species   |
| <b>Storage</b>          | Stable for 3-4 days @ 4°C.<br>Store below -20°C (below -70°C for prolonged storage).<br>Aliquot to avoid repeated cycles of freeze/thawing.  |
| <b>Other</b>            | See Hayes AJ et al (2008) Methods 45: 10 - 21  |

|                              |  |
|------------------------------|--|
| <b>Application notes</b>     | • <b>Western blotting:</b> 1/100 (e.g. 50µl to 5 ml with blocking buffer)      |
| <b>Recommended dilutions</b> | • <b>Immunohistochemistry:</b> 1/20 (e.g. 20µl to 400µl with blocking buffer). |

Other applications have not been tested.

Optimal dilutions/concentrations should be determined by the end user.

|                   |  |
|-------------------|--|
| <b>References</b> | 1) Caterson B. (2012). Chondroitin sulphate glycosaminoglycans: fun for some and confusion for others. Int. J. of Exp. Path. 93: 1 – 10 PubMed: <a href="#">22264297</a>   |
|                   | 2) Hayes AJ, Hughes CE & Caterson B (2008). Antibodies and immunohistochemistry in extracellular matrix research. Methods 45: 10 - 21 PubMed: <a href="#">18442701</a>   |
|                   | 3) Caterson B, Christner JE, Baker JR & Couchman JR (1985). The production and characterization of monoclonal antibodies directed against connective tissue proteoglycans. Federation Proceedings 44: 386 - 393. PubMed: <a href="#">2578417</a> |
|                   | 4) Couchman JR, Caterson B, Christner JE & Baker JR (1984). Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues. Nature 307: 650 – 652. PubMed: <a href="#">6420711</a>   |